While market darlings come and go, a select group of companies achieves sustained outperformance through a powerful trifecta: rising sales, expanding profitability, and efficient capital use. We examine three such names that have delivered triple-digit returns over the past five years.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
Shares of quantum computing pioneer Rigetti Computing have delivered substantial returns over the past year, dramatically outperforming the broader market. Yet, analysts caution that sky-high valuations may have raced far ahead of the company's current commercial reality.
A social media poll by billionaire Mark Cuban reveals a near-even split on which part of U.S. health insurance is more financially painful—premiums or deductibles. The results, and the outpouring of personal stories in the replies, underscore a system many describe as forcing impossible choices amid relentlessly rising costs.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
Venture capitalist Chamath Palihapitiya scored a monumental win with Nvidia's $20.6 billion purchase of AI chipmaker Groq, yet the investor reveals a profound sense of melancholy, highlighting the psychological complexities behind blockbuster deals.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
A dramatic surge in SuperX AI Technology's share price has spotlighted its concentrated ownership structure, with private companies holding a dominant 34% stake and reaping the largest rewards from the recent rally. As the AI-driven healthcare sector heats up, investor attention turns to who holds the reins at this promising but closely held firm.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
